Cannabis and multiple sclerosis

References

• World Health Organization. Management of substance abuse: cannabis. 2019. Cited 2020 Mar 10. Available at: https://www.who.int/substance_abuse/publications/cannabis/en/.
   Google Scholar
• Cannabis CS. Neuropsychiatric Disorders: an Updated Review. Acta Neurol Taiwan. 2019;28(2):27‐39.
   Google Scholar
• Adler JN, Colbert JA. Medicinal use of marijuana–polling results. N Engl J Med. 2013;368:e30. 8.
   Web of Science ®Google Scholar
• Kondrad E, Reid A. Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med. 2013;26:52–60.
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Eisenberg E. Medical cannabis: A forward vision for the clinician. Eur J Pain. 2018;22(3):485–491.
   PubMed Web of Science ®Google Scholar
• Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180–188.
   PubMedGoogle Scholar
• MacDonald K, Pappas K. Why not pot? Innov Clin Neurosci. 2016;13:13–22.
   PubMedGoogle Scholar
• Clark PA, Capuzzi K, Fick C. Medical marijuana: medical necessity versus political agenda. Med Sci Monit. 2011;17:RA249–RA261.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4):692–698.
   PubMed Web of Science ®Google Scholar
• McPartland JM, Duncan M, Di Marzo V, et al. Are cannabidiol and ∆9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2014;172:737–753.
   Web of Science ®Google Scholar
• Alexander S. Common receptors for endocannabinoid-like mediators and plant cannabinoids. In: Di Marzo V, Wang J, editors. The endocannabinoidome. London: Academic Press; 2015. p. 153–167.
   Google Scholar
• McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9:e89566.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci. 2012;367:3216–3228.
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5:529–552.
   PubMedGoogle Scholar
• Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409–416.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360.
   PubMed Web of Science ®Google Scholar
• Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86–95.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219–2227.
   PubMed Web of Science ®Google Scholar
• Silins E, Horwood LJ, Patton GC, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286–293.
   PubMed Web of Science ®Google Scholar
• Kalla A, Krishnamoorthy PM, Gopalakrishnan A, et al. Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample. J Cardiovasc Med (Hagerstown). 2018;19(9):480–484.
   PubMed Web of Science ®Google Scholar
• Leung MCK, Silva MH, Palumbo AJ, et al. Adverse outcome pathway of developmental neurotoxicity resulting from prenatal exposures to cannabis contaminated with organophosphate pesticide residues. Reprod Toxicol. 2019;85:12–18.
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12‐19.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1–13.
   PubMed Web of Science ®Google Scholar
• Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1‐8.
   Web of Science ®Google Scholar
• Ford TC, Hayley AC, Downey LA, et al. Cannabis: an overview of its adverse acute and chronic effects and its implications. Curr Drug Abuse Rev. 2017;10(1):6–18.
   PubMedGoogle Scholar
• Clark AJ, Ware MA, Yazer E, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62(11):2098–2100.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Germanos R, Weier M, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 2018;18(2):8.
   PubMed Web of Science ®Google Scholar
• No authors listed. Cannabis-based medicines - GW pharmaceuticals: high CBD, high THC, medicinal cannabis - GW pharmaceuticals, THC:CBD. Drugs R.D. 2003;4(5):306–309.
   PubMedGoogle Scholar
• Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729–1743.
   PubMed Web of Science ®Google Scholar
• Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17(1):85–95.
   PubMed Web of Science ®Google Scholar
• May MB, Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res. 2016 12;8:49–55.
   PubMed Web of Science ®Google Scholar
• Badowski ME, Yanful PK. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag. 2018;14:643–651.
   PubMed Web of Science ®Google Scholar
• Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res. 2019;8:F1000 Faculty Rev–234.
   Google Scholar
• Billakota S, Devinsky O, Marsh E. Cannabinoid therapy in epilepsy. Curr Opin Neurol. 2019;32(2):220–226.
   PubMed Web of Science ®Google Scholar
• Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017;70(Pt B):288–291.
   PubMedGoogle Scholar
• Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Sub Abuse. 1987;7(1):39–50.
   PubMedGoogle Scholar
• Greenberg HS, Werness SA, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994;55(3):324–328.
   PubMed Web of Science ®Google Scholar
• Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404–1407.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–1526.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–441.
   PubMed Web of Science ®Google Scholar
• Brady CM, Das Gupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10(4):425–433.
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417–424.
   PubMed Web of Science ®Google Scholar
• Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62(7):1105–1109.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–1669.
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812–819.
   PubMed Web of Science ®Google Scholar
• Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636–641.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639–645.
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296.
   PubMed Web of Science ®Google Scholar
• Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41–47.
   PubMed Web of Science ®Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349–1359.
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–459.
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125–1132.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143–1150.
   PubMed Web of Science ®Google Scholar
• Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984–997.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice–results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71(5–6):271–279..
   PubMed Web of Science ®Google Scholar
• Coghe G, Pau M, Corona F, et al. Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol. 2015;262(11):2427–2472.
   Web of Science ®Google Scholar
• Leocani L, Nuara A, Houdayer E, et al. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol. 2015;262(11):2520–2527.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Trojano M. Tetrahydrocannabinol:cannabidioloromucosal spray for multiple sclerosis-related resistant spasticity in daily practice. Eur Neurol. 2016;76(5–6):216–226.
   PubMed Web of Science ®Google Scholar
• Ferrè L, Nuara A, Pavan G, et al. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci. 2016;37(2):235–242.
   PubMed Web of Science ®Google Scholar
• Patti F, Messina S, Solaro C, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016;87(9):944–951.
   PubMed Web of Science ®Google Scholar
• Russo M, Naro A, Leo A, et al. Evaluating Sativex® in neuropathic pain management: a clinical and neurophysiological assessment in multiple sclerosis. Pain Med. 2016;17(6):1145–1154.
   PubMed Web of Science ®Google Scholar
• Schimrigk S, Marziniak M, Neubauer C, et al. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78(5–6):320–329.
   PubMed Web of Science ®Google Scholar
• Messina S, Solaro C, Righini I, et al. Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study). PLoS One. 2017;12(8):e0180651.
   PubMed Web of Science ®Google Scholar
• Maniscalco GT, Aponte R, Bruzzese D, et al. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. Neurol Sci. 2018;39(1):97–102.
   PubMed Web of Science ®Google Scholar
• Turri M, Teatini F, Donato F, et al. Pain modulation after oromucosal cannabinoid spray (sativex®) in patients with multiple sclerosis: a study with quantitative sensory testing and laser-evoked potentials. Medicines (Basel). 2018 21;5(3):E59..
   PubMedGoogle Scholar
• Castelli L, Prosperini L, Pozzilli C. Balance worsening associated with nabiximols in multiple sclerosis. Mult Scler. 2019;25(1):113–117.
   PubMed Web of Science ®Google Scholar
• Markovà J, Essner U, Akmaz B, et al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129(2):119–128.
   PubMed Web of Science ®Google Scholar
• Carotenuto A, Costabile T, De Lucia M, et al. Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. J Neurol. 2020 Mar 2 Epub. DOI:10.1007/s00415-020-09739-x.
   Web of Science ®Google Scholar
• Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6.
   PubMed Web of Science ®Google Scholar
• Hall W, Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction. 2016;111(10):1764–1773.
   PubMed Web of Science ®Google Scholar
• Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017 Apr;42:30–35.
   PubMed Web of Science ®Google Scholar
• Legal medical cannabis. Cited 2020 Feb 28. https://www.fool.com/investing/2018/07/21/these-30-countries-have-legalized-medical-marijuan.aspx.
   Google Scholar
• Legal medical cannabis. Cited 2020 Feb 28. https://newfrontierdata.com/cannabis-insights/europes-medical-cannabis-programs-countries-to-watch.
   Google Scholar
• Knöss W, van de Velde M, Sandvos C, et al. Key elements of legal environments for medical use of cannabis in different countries. Bundesgesundheitsbla. 2019;62(7):855–860.
   Google Scholar
• Carliner H, Brown QL, Sarvet AL, et al. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. 2017;104:13–23.
   PubMed Web of Science ®Google Scholar
• Celius EG, Vila C. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. Brain Behav. 2018;8(5):e00962.
   PubMed Web of Science ®Google Scholar
• Wade D. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? Expert Rev Neurother. 2012;12(4 Suppl):9–14.
   PubMedGoogle Scholar
• Arroyo González R. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert Rev Neurother. 2018;18(10):785–791.
   PubMed Web of Science ®Google Scholar
• Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler. 2016;22(11):1386–1396.
   PubMed Web of Science ®Google Scholar
• Safarpour Y, Mousavi T, Jabbari B. Botulinum toxin treatment in multiple sclerosis-a review. Curr Treat Options Neurol. 2017;19(10):33.
   PubMed Web of Science ®Google Scholar
• Latino P, Castelli L, Prosperini L, et al. Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurol Sci. 2017;38(10):1841–1848.
   PubMed Web of Science ®Google Scholar
• Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen. J Rehabil Med. 2017 Mar 6;49(3):193–203..
   PubMed Web of Science ®Google Scholar
• Sammaraiee Y, Yardley M, Keenan L, et al. Intrathecal baclofen for multiple sclerosis related spasticity: A twenty-year experience. Mult Scler Relat Disord. 2019;27:95–100.
   PubMed Web of Science ®Google Scholar
• Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):593–604.
   PubMed Web of Science ®Google Scholar